Ozempic’s hidden pregnancy risk few women know about

The Rise of GLP-1 Agonists: A Medical Revolution

Glucagon-like peptide-1 (GLP-1) receptor agonists represent a transformative class of medications that have reshaped the treatment landscape for both type 2 diabetes and, more recently, chronic weight management. These drugs mimic the action of a natural hormone, GLP-1, which is released in the gut in response to food intake. Their multifaceted mechanism of action includes stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and promoting a sense of satiety by acting on brain receptors. This combination effectively lowers blood glucose levels and reduces appetite, leading to significant weight loss.

The journey of GLP-1 agonists began in the early 2000s, with exenatide (Byetta) receiving its first approval for type 2 diabetes in 2005. Subsequent years saw the introduction of longer-acting formulations and newer molecules like liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and semaglutide (Ozempic, Wegovy). While initially lauded for their efficacy in diabetes management, their profound weight-loss effects quickly garnered attention. Liraglutide (Saxenda) was among the first GLP-1 agonists to gain specific approval for chronic weight management in non-diabetic individuals in several countries, including Australia, followed by semaglutide (Wegovy).

The ascent of these medications into mainstream consciousness has been meteoric, driven by compelling clinical trial data demonstrating significant weight reduction and cardiovascular benefits, coupled with extensive media coverage and, at times, social media virality. Drugs like Ozempic, though primarily approved for type 2 diabetes, have been widely prescribed off-label for weight loss, particularly before dedicated weight-loss formulations like Wegovy became broadly available. This surge in popularity has created a global market worth billions, fundamentally altering approaches to managing obesity, a condition that affects millions worldwide and is a major contributor to numerous chronic diseases. The global prevalence of obesity has nearly tripled since 1975, with over 1 billion people currently affected, highlighting the immense demand for effective therapeutic interventions. This context is crucial for understanding the widespread adoption of GLP-1 agonists and the increasing number of individuals, particularly women of childbearing age, now exposed to these powerful medications.

Unpacking the Flinders University Study: A Decade of Data

The comprehensive research conducted by Flinders University researchers, led by pharmacist Associate Professor Luke Grzeskowiak from the College of Medicine and Public Health, provides an unprecedented insight into the real-world prescribing patterns and associated reproductive health considerations in Australia. The study’s robust methodology involved analysing de-identified data from over 1.6 million women aged 18 to 49 who attended general practices across Australia between 2011 and 2022. This extensive dataset allowed researchers to track the prescribing trends of GLP-1 receptor agonists and concurrently monitor contraception use and pregnancy outcomes.

Of the 18,010 women identified as having received a first prescription for a GLP-1 receptor agonist during this eleven-year period, a striking finding emerged: only 21% had reported using any form of contraception at the time of prescription. This figure stands in stark contrast to general contraception usage rates in Australia, where a significant majority of sexually active women of reproductive age typically use some form of birth control. The disparity underscores a critical lapse in the clinical management pathway for these medications, particularly given the known, albeit limited, data on their potential risks during pregnancy.

Alarming Contraception Gap and Shifting Prescribing Trends

A key revelation from the study was the dramatic shift in the primary indication for GLP-1 agonist prescriptions. While originally developed and approved for type 2 diabetes, the research unequivocally demonstrated that most prescriptions are now being issued to women without a diabetes diagnosis, predominantly for weight loss. Associate Professor Grzeskowiak highlighted this trend, stating that in 2022 alone, more than 6,000 women initiated GLP-1 treatment, and over 90% of these individuals did not have a diabetes diagnosis. This indicates a widespread adoption of these drugs for their metabolic and weight-reducing properties, moving beyond their initial therapeutic niche.

"We’re seeing widespread use of these medications among women of childbearing age, but very little evidence that contraception is being considered as part of routine care," Associate Professor Grzeskowiak commented, emphasising the gravity of the situation. He further cautioned, "These medications can be incredibly helpful, but they’re not risk-free, especially during pregnancy." This statement encapsulates the core dilemma: balancing the significant benefits of GLP-1s for weight management and metabolic health against the potential, and often overlooked, reproductive risks.

The study’s findings paint a concerning picture of a gap in routine clinical practice where comprehensive discussions about reproductive health and contraception are either not occurring or are not adequately documented when GLP-1s are prescribed to women in their reproductive years. This oversight could be attributed to several factors, including the rapid uptake of these medications, potentially insufficient awareness among some prescribers regarding the nuances of reproductive safety, and the time constraints inherent in general practice consultations.

Unintended Pregnancies and Fertility Insights

Beyond the contraception gap, the study also meticulously tracked pregnancy outcomes. It revealed that 2.2% of women became pregnant within six months of initiating GLP-1 treatment. While this percentage might appear small, it represents a significant number of individuals potentially exposed to these drugs during critical early stages of fetal development. The pregnancy rates were notably higher among certain demographics: younger women with a diagnosis of diabetes, and women without diabetes who were in their early thirties. These groups represent a significant portion of women who might be actively trying to conceive or are at a higher risk of unintended pregnancy.

A particularly intriguing and somewhat paradoxical finding was related to women with polycystic ovary syndrome (PCOS). The study observed that women with PCOS were twice as likely to conceive while on GLP-1 treatment. This suggests a potential unintended consequence of weight loss facilitated by these medications: an improvement in fertility. PCOS is a common endocrine disorder characterised by hormonal imbalances, irregular periods, and often, insulin resistance and obesity, which can impair fertility. Weight loss is a well-established intervention to improve reproductive outcomes in women with PCOS. While improved fertility is a positive outcome for those actively trying to conceive, it further underscores the critical need for contraception discussions for women who are not, or for whom pregnancy would be considered high-risk.

Crucially, the study provided empirical evidence supporting the efficacy of contraception in mitigating pregnancy risk. Women who were documented as using contraception at the time of receiving their GLP-1 prescription had a significantly lower risk of becoming pregnant. This reinforces the straightforward solution to the identified problem: integrating effective contraception counselling and provision into the prescribing process.

Known Risks and International Guidance

The concern surrounding GLP-1 agonist use during pregnancy is not new, although human data remains limited. A previous review of animal studies conducted by the University of Amsterdam linked GLP-1 exposure during pregnancy to adverse fetal outcomes, including reduced fetal growth and skeletal abnormalities. While direct extrapolation from animal models to human pregnancies requires caution, these findings raise significant red flags and underscore the potential for teratogenic effects. Pharmaceutical manufacturers themselves typically advise against the use of GLP-1 agonists during pregnancy and recommend discontinuing the medication well in advance of conception, often advising a washout period due to their prolonged half-life.

Globally, regulatory bodies and medical organisations have issued guidance reflecting these concerns. For instance, the UK’s regulatory framework explicitly advises that women using GLP-1 receptor agonists should avoid pregnancy and utilise effective contraception. Associate Professor Grzeskowiak pointed out a critical disparity: "Whilst the UK advises that women using GLP-1 receptor agonists should avoid pregnancy and use effective contraception, this advice is not being followed consistently in Australian clinical practice." This divergence highlights a potential gap in the consistent application of best practice guidelines across different healthcare systems, or at least in the practical implementation within Australian general practice settings.

The absence of robust human data on GLP-1 agonist exposure during pregnancy is a significant challenge. Conducting clinical trials on pregnant women is ethically complex, making reliance on observational studies, pregnancy registries, and post-market surveillance essential. Until more definitive human data becomes available, a precautionary principle dictates that these medications should be avoided during pregnancy, necessitating stringent contraception measures for women of childbearing potential.

The Broader Landscape: Challenges and Opportunities

The findings of the Flinders University study resonate across several facets of public health and clinical practice, presenting both challenges and opportunities for improvement.

Prescriber Awareness and Education: The rapid adoption of GLP-1 agonists, particularly for weight management, may have outpaced comprehensive education on their reproductive health implications for all prescribers. General practitioners, who are often at the frontline of prescribing these medications, manage a vast array of patient needs. Ensuring they are fully equipped with the latest guidelines and possess the time and resources to conduct thorough reproductive health counselling is paramount. Educational initiatives from professional bodies like the Royal Australian College of General Practitioners (RACGP) and the Pharmaceutical Society of Australia (PSA) are crucial.

Patient Empowerment and Informed Consent: Patients need to be fully informed about the risks and benefits of any medication, especially those with implications for pregnancy. The study suggests a potential lack of awareness among women themselves regarding the necessity of contraception while on GLP-1s. Empowering patients with clear, accessible information and encouraging them to actively engage in discussions about their reproductive plans with their healthcare providers is vital for shared decision-making.

Regulatory Oversight and Guideline Harmonization: The inconsistency in advice implementation between Australia and the UK signals a need for clearer, more explicit, and consistently applied national guidelines. The Therapeutic Goods Administration (TGA) in Australia, in collaboration with medical professional bodies, could play a pivotal role in reviewing and updating practice recommendations to ensure they are robust and widely disseminated. This could involve mandating specific counselling points at the time of prescription or integrating alerts within electronic prescribing systems.

The Intersection of Obesity, Fertility, and Medication: The increased likelihood of conception in women with PCOS on GLP-1s adds another layer of complexity. While weight loss can improve fertility, this benefit needs to be carefully managed for women who are not planning a pregnancy or for whom pregnancy might carry other health risks. This highlights the need for a holistic approach to patient care, considering all aspects of their health and life stage.

Call to Action: Towards Safer Prescribing Practices

Associate Professor Grzeskowiak’s call to action is unequivocal: "We need to ensure that reproductive health is part of every conversation when these drugs are prescribed to any women of childbearing age." This mandate extends beyond a simple checklist; it requires a thoughtful, empathetic, and comprehensive discussion that acknowledges a woman’s reproductive intentions, her current contraception use, and the potential implications of GLP-1s.

Furthermore, he stressed the critical need for clearer practice recommendations and guidelines for those prescribing GLP-1s to women, ensuring their safe and effective use. Such guidelines should outline specific requirements for contraception counselling, documentation, and follow-up. This could include mandatory discussions about discontinuing the medication prior to planned conception and ensuring a sufficient washout period, as recommended by manufacturers.

The advice to patients is equally clear: "Our advice is to speak to your GP about the risks and benefits of GLP-1 medicines before taking them, and only take those prescribed by a healthcare professional." This reinforces the importance of the doctor-patient relationship as the cornerstone of safe medication use.

Future Research and Policy Directions

The authors of the Flinders University study rightly conclude that further studies evaluating the impact of these medications on pregnancy and unborn babies are warranted. This includes establishing national pregnancy registries for women exposed to GLP-1 agonists, which can provide invaluable real-world data on fetal outcomes. Longitudinal observational studies following cohorts of women who have used these medications during pregnancy are also essential to build a more comprehensive evidence base.

Policy interventions could also include leveraging technology, such as embedding prompts within electronic health records or e-prescribing software that alert prescribers to discuss contraception when GLP-1s are prescribed to women of reproductive age. Pharmacists, as key healthcare providers, also have a crucial role in reinforcing contraception messages at the point of dispensing.

Ultimately, the Flinders University study serves as a vital alarm bell, illuminating a significant gap in healthcare delivery for women taking GLP-1 receptor agonists. By highlighting the low rates of contraception use and the associated risks of unintended pregnancies, it provides an urgent impetus for healthcare professionals, regulatory bodies, and patients to collaborate in ensuring that the benefits of these powerful medications are realised without compromising the safety and well-being of future generations.

Acknowledgements: Luke Grzeskowiak receives salary support from a Channel 7 Children’s Research Foundation Fellowship (CRF-210323). We also acknowledge the contributions of members of the SPHERE Centre of Research Excellence in Women’s Sexual and Reproductive Health in Primary Care (SPHERE 2.0 CRE), which is funded by the National Health and Medical Research Council (APP2024717).